ATIM-39. PHASE 2 OPEN-LABELED STUDY OF ADJUVANT TEMOZOLOMIDE PLUS TUMOR TREATING FIELDS PLUS PEMBROLIZUMAB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2-THE-TOP)

BACKGROUND/OBJECTIVE: Tumor treating Fields (TTFields) plus maintenance temozolomide is an approved standard treatment for newly diagnosed Glioblastoma (GBM). TTFields are alternating electric fields of low intensity and intermediate frequency delivered non-invasively via transducer arrays to tumor...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Tran, David, Warren, Sonisha, Allen, Anne, Sampson, Deborah, Chen, Dongjiang, Thomas, Nagheme, Greene, Valerie, Rahman, Maryam, Ghiaseddin, Ashley
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Adult Clinical Trials–Immunologic
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847508/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.038
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items